Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 2/20 | 0.55 |
| ▸ | GRAMD1A | Q96CP6 | 1/20 | 0.52 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | FABP4 | P15090 | 1/20 | 0.42 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.42 |
| ▸ | GCK | P35557 | 6/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | F10 | P00742 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL210375 | 0.99 | ADORA1 (0.54) | ADORA1GRAMD1AESR2MAPTKDM4E | |
| SCHEMBL16794209 | 0.91 | ADORA1 (0.47) | ADORA1GRAMD1AESR2MAPTKDM4E | |
| SCHEMBL31143542 | 0.89 | ADORA1 (0.51) | ADORA1GRAMD1AESR2MAPTKDM4E | |
| SCHEMBL12035965 | 0.88 | ADORA1 (0.46) | ADORA1GRAMD1AESR2MAPTKDM4E | |
| SCHEMBL3441645 | 0.88 | GRAMD1A (0.52) | ADORA1GRAMD1AMAPTKDM4EGCK | |
| Lithium Ion SCHEMBL210376 | 0.88 | GRAMD1A (0.50) | ADORA1GRAMD1AESR2MAPTKDM4E | |
| SCHEMBL17993838 | 0.87 | GRAMD1A (0.53) | ADORA1GRAMD1AESR2MAPTKDM4E | |
| SCHEMBL1504298 | 0.87 | ADORA1 (0.45) | ADORA1GRAMD1AESR2MAPTKDM4E | |
| SCHEMBL26024092 | 0.84 | GRAMD1A (0.48) | ADORA1GRAMD1AESR2MAPTKDM4E | |
| SCHEMBL978537 | 0.84 | ADORA1 (0.59) | ADORA1GRAMD1AMAPTKDM4EGCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4665330-A1 | PLASMA KALLIKREIN INHIBITORS | Merck Sharp & Dohme LLC (US) | 2025-12-24 | — | — | EP | disclosed |
| WO-2024173196-A1 | PLASMA KALLIKREIN INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2024-08-22 | — | — | WO | disclosed |
| CN-112384500-B | Immunomodulator, composition and preparation method thereof | 贝达药业股份有限公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-111936475-B | Immunomodulator, composition and preparation method thereof | 贝达药业股份有限公司 | 2024-05-10 | — | — | CN | disclosed |
| US-11873309-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2024-01-16 | — | — | US | disclosed |
| EP-3596060-B1 | NEW BICYCLIC COMPOUNDS AS ATX INHIBITORS | HOFFMANN LA ROCHE (CH) | 2023-09-20 | — | — | EP | disclosed |
| EP-4137489-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | Incyte Corporation (US) | 2023-02-22 | — | — | EP | disclosed |
| US-11572356-B2 | Biaryl inhibitors of Bruton's tyrosine kinase | BIOGEN MA INC. (US) | 2023-02-07 | — | — | US | disclosed |
| CN-109890819-B | Heterocyclic compounds as immunomodulators | 因赛特公司 | 2022-11-22 | — | — | CN | disclosed |
| US-20220332705-A1 | BIARYL INHIBITORS OF BRUTON'S TYROSINE KINASE | BIOGEN MA INC. | 2022-10-20 | — | — | US | disclosed |
| US-7192968-B2 | Ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-20 | — | — | US | disclosed |
| US-7192968-B2 | Ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-20 | — | — | US | disclosed |
| US-7192968-B2 | Ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-20 | — | — | US | disclosed |
| US-20060004009-A1 | Ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-01-05 | — | — | US | disclosed |
| US-20050245565-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| US-20050020645-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-01-27 | — | — | US | disclosed |
| US-20040122063-A1 | Ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-06-24 | — | — | US | disclosed |
| EP-1415992-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-05-06 | — | — | EP | disclosed |
| EP-1405852-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-07 | — | — | EP | disclosed |
| EP-1270557-A1 | ETHYLENEDIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11572356-B2 | Biaryl inhibitors of Bruton's tyrosine kinase | ABL1, BTK, LYN | ADORA1 4562/4885GRAMD1A 3503/4885ESR2 3301/4885 |
| US-20060004009-A1 | Ethylenediamine derivatives | F2, ECE1, MLLT1 | ADORA1 1447/4885GRAMD1A 1049/4885ESR2 129/4885 |
| US-20050020645-A1 | Diamine derivatives | C9, C1S, C1R | ADORA1 1667/4885GRAMD1A 2556/4885ESR2 1879/4885 |
| US-20050245565-A1 | Diamine derivatives | C9, C1S, C1R | ADORA1 1667/4885GRAMD1A 2556/4885ESR2 1879/4885 |
| US-11873309-B2 | Heterocyclic compounds as immunomodulators | CD74, IL2, ICOS | ADORA1 1316/4885GRAMD1A 4670/4885ESR2 1345/4885 |
| US-20220332705-A1 | BIARYL INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, LYN | ADORA1 4562/4885GRAMD1A 3503/4885ESR2 3301/4885 |
| US-20040122063-A1 | Ethylenediamine derivatives | ECE1, F2, ECE2 | ADORA1 1150/4885GRAMD1A 1143/4885ESR2 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.